The rehabilitation robotics market has long been a graveyard of ambitious academic spin-offs—expensive prototypes that never quite make the leap from hospital pilot to commercial traction. Wearable Robotics, a decade-old company born from the labs of Scuola Superiore Sant'Anna in Pisa, is wagering it can defy those odds.
The startup is preparing to close a €5 million Series A round, expected to be announced in April 2026, led by CDP Venture Capital's Acceleratori Fund, with backing from an unusually broad coalition of Italian institutional investors. The capital comes at what may be an inflection point: Wearable Robotics projects that more than 50 units of its ALEx RS upper-limb rehabilitation exoskeleton will be in clinical use across international markets by that time—a figure that, if achieved, would place it among a small cohort of European robotics companies that have moved beyond the pilot stage.
Whether that momentum translates into sustainable growth is another question entirely.
The Pitch: Modular Rehab Robotics, Built for Scale
Wearable Robotics plans to use the fresh capital to expand its product lineup with modular robotic systems tailored to different rehabilitation scenarios. The company is also navigating regulatory approvals in target markets and aiming to strengthen its commercial presence internationally, with North America emerging as a key focus.
There are early signs the strategy may be gaining traction. The company anticipates its first ALEx RS installation in North America by mid-2025, and a post from March this year noted deployment at Grupo 5 CIAN Madrid in Spain. For a company that spent its first years largely confined to Italian and European rehab centers, the geography is shifting.
Still, the company remains tight-lipped on specifics—revenue figures, exact hospital partnerships, and detailed timelines are conspicuously absent from public disclosures.
What ALEx RS Actually Does
At its core, ALEx RS is a dual-arm exoskeleton designed to assist patients recovering from stroke, spinal cord injury, or other neuromotor impairments. The device offers five degrees of freedom—four active, one passive—and incorporates virtual reality content to support bilateral therapy, mirror therapy, and what the company calls "record-and-play" rehabilitation modes.
CE-compliant and classified as a Class IIa medical device under the Medical Device Directive (MDD), the system has been commercially available since 2019. That's a longer runway than many robotics startups manage before fizzling out, though it also raises questions about why the installed base hasn't grown faster.
Wearable Robotics has previewed ALEx RS 2.0, an upgraded iteration it teased at WHX Dubai in February. The company says the new platform will improve performance, usability, and scalability, but has not disclosed regulatory timelines or when—or if—the updated version will reach clinics.
Beyond rehabilitation, the company operates a separate division called NEXUM Industry, which builds load-handling exoskeletons designed to reduce musculoskeletal strain in manual labor settings. It's a hedge, perhaps, against the slower-than-expected adoption curve in clinical robotics.
A Decade in the Making
Wearable Robotics was founded in 2014 with an exclusive license for six industrial patents from Sant'Anna. The company later acquired the full patent family in 2022—a move that gave it greater freedom to commercialize but also underscored its bet on proprietary technology in a crowded field.
Funding has come in increments. A €2.5 million round in April 2023 brought in MITO Technology and LIFTT as leads, alongside CDP Venture Capital and a cohort of private investors through equity crowdfunding. An earlier €2 million raise via ClubDealOnline in November 2021 helped extend the runway.
According to LinkedIn, the company's headcount sits somewhere in the 11–50 employee range. CEO and co-founder Lucia Lencioni oversees commercial strategy, while CTO Fabio Salsedo leads the technical side—both figures with deep roots in the company's academic origins.
Italy's Bet on Deep Tech
The Series A syndicate reflects a broader trend: Italy's institutional investors are leaning harder into robotics commercialization. Beyond CDP Venture Capital, the round includes MITO Technology (via the Mito Tech Transfer Fund), LIFTT, SIMEST (deploying resources from the Fund 394/81 Venture Capital and Equity Investment Section), RoboIT—the National Technology Transfer Hub for Robotics and Industrial Automation—and Toscana Next, a co-investment vehicle subscribed by Tuscan banking foundations including CR Firenze, CR Lucca, Monte dei Paschi di Siena, and Caript.
It's a stack of names that signals official enthusiasm, if not yet proof of market demand.
A Crowded, Unforgiving Market
Wearable Robotics enters a competitive landscape where survival, let alone dominance, is far from guaranteed. Publicly traded players like Ekso Bionics and Lifeward (formerly ReWalk) have struggled to achieve profitability despite years of commercial operations. Meanwhile, well-funded private ventures such as Wandercraft—which announced a $75 million Series D last June and is preparing to launch a personal self-balancing exoskeleton—are raising the stakes.
The challenge isn't just technical; it's economic. Rehabilitation robotics systems are expensive, reimbursement pathways remain murky, and adoption by hospitals and clinics often hinges on proving not just efficacy but cost-effectiveness. Wearable Robotics will need to clear all three hurdles if it wants to turn 50 deployed units into 500.
For now, the company has capital, a growing installed base, and a coalition of backers willing to bet that Italian robotics can compete on the global stage. Whether that's enough remains to be seen.
